The global cellular health screening market size was valued at USD 2.78 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 9.2% from 2023 to 2030. Over the projected period, the importance of precision medicine is expected to increase along with the requirement to analyze biomarkers for aging and cellular health in general. In addition, cellular health screening plays a crucial role in monitoring the body’s reaction to treatment regimens, which is anticipated to contribute to the growth of the market. Companies involved in delivering cellular health screening goods and services noticed a reduction in their sales and base testing volume as a result of the COVID-19 pandemic.

The use of home diagnostic tests is significantly rising globally. The growing number of campaigns to educate the public about the signs of chronic diseases and how to prevent them in order to contain disease epidemics are expected to fuel growth. 

Gather more insights about the market drivers, restrains and growth of the Global Cellular Health Screening Market

Cellular Health Screening Market Report Highlights

• By test type, single test panels held the largest share in 2022. This is attributed to high specificity, easy customization, and increasing product availability in the market
• In the single test panels segment, the oxidative stress tests captured the largest share in 2022. These tests aid in cancer, respiratory diseases, diabetes, cardiovascular diseases, and other diseases Based on sample type, the blood sample segment accounted for the largest share in 2022. The growing incidence of infectious diseases, emergence of newer pathogens, increasing demand for donated blood, and rising number of blood donations have contributed to the rising demand for blood samples for cellular health screening
• By collection site, hospitals captured the largest revenue share in 2022. A major part of the general population relies on these long-term facilities for diagnosis, treatment, and management of diseases, thus driving the segment
• North America accounted for the largest market share in 2022. An increase in the importance of Healthy Life Expectancy (HALE) and increasing number of government initiatives focused on preventive healthcare are some of the key factors expected to boost the market growth in the region
• Asia Pacific is expected to witness the fastest growth throughout the forecast period. Improving adoption and awareness of telomere performance programs and growing awareness of healthy life expectancy have contributed to regional growth

Browse through Grand View Research's Clinical Diagnostics Industry Research Reports.

• The global point of care infectious disease testing market size was valued at USD 11.40 billion in 2023 and is projected to grow at a CAGR of 4.3% from 2024 to 2030.
• The global transplant diagnostics market size was valued at USD 5.97 billion in 2023 and is projected to grow at a CAGR of 7.3% from 2024 to 2030. 

Segments Covered in the Report

Grand View Research has segmented the global cellular health screening market on the basis of test type, sample type, collection site and region:

Cellular Health Screening Test Type Outlook (Revenue, USD Million, 2018 - 2030)

• Single Test Panels
  • Telomere Tests
  • Oxidative Stress Tests
  • Inflammation Tests
  • Heavy Metals Tests
• Multi-test Panels

Cellular Health Screening Sample Type Outlook (Revenue, USD Million, 2018 - 2030)

• Blood
• Saliva
• Serum
• Urine

Cellular Health Screening Collection Site Outlook (Revenue, USD Million, 2018 - 2030)

• Home
• Office
• Hospital
• Diagnostic Labs

Cellular Health Screening Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
  • U.S.
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait

Order a free sample PDF of the Cellular Health Screening Market Intelligence Study, published by Grand View Research.